Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xuanzhu Biopharmaceutical CoHKSE:02575 +3.21%11 PB Ratio is 4.41 as of Aug. 10, 2026, which is 74% below its 10-year median of 17.11. GuruFocus rates HKSE:02575 with a GF Score™ of 11/100. The stock has 1 warning sign investors should review. Among 922 Drug Manufacturers companies, Xuanzhu Biopharmaceutical Co ranks worse than 77.77% on this metric.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Xuanzhu Biopharmaceutical Co PB Ratio Related Terms
Xuanzhu Biopharmaceutical Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xuanzhu Biopharmaceutical Co PB Ratio Chart
Xuanzhu Biopharmaceutical Co Annual Data
Trend
Dec23
Dec24
Dec25
PB Ratio
0.00
0.00
24.08
Xuanzhu Biopharmaceutical Co Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
PB Ratio
0.00
0.00
0.00
0.00
24.08
HKSE:02575 vs ZTS: PB Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Xuanzhu Biopharmaceutical Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xuanzhu Biopharmaceutical Co PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Xuanzhu Biopharmaceutical Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Xuanzhu Biopharmaceutical Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Xuanzhu Biopharmaceutical Co (HKSE:02575) has a PB Ratio of 4.41 as of Aug. 10, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Xuanzhu Biopharmaceutical Co and its competitors. This is 74% below median its historical median of 17.11. Over the past decade, Xuanzhu Biopharmaceutical Co's PB Ratio has ranged from 3.76 to 42.06. According to the industry distribution chart, Xuanzhu Biopharmaceutical Co ranks #717 out of 922 companies in the Drug Manufacturers industry, placing it in the top 77.8%.
Is Xuanzhu Biopharmaceutical Co's PB Ratio too high?
Xuanzhu Biopharmaceutical Co's current PB Ratio of 4.41 is 74% below median its 10-year median of 17.11. Over the past 10 years, this metric has ranged from a low of 3.76 to a high of 42.06. The Drug Manufacturers industry median PB Ratio is 1.96. Xuanzhu Biopharmaceutical Co's value of 4.41 is 125% above this industry median. Based on the distribution chart, Xuanzhu Biopharmaceutical Co ranks #717 out of 922 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Xuanzhu Biopharmaceutical Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Xuanzhu Biopharmaceutical Co's PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Xuanzhu Biopharmaceutical Co ranks #717 out of 922 companies for PB Ratio. This places Xuanzhu Biopharmaceutical Co in the lower half of its industry. The industry median PB Ratio is 1.96. Xuanzhu Biopharmaceutical Co's value of 4.41 is 125% above this benchmark. Historically, Xuanzhu Biopharmaceutical Co's own PB Ratio has ranged from 3.76 to 42.06 over the past decade. While the company's 10-year median is 17.11 vs. the industry median of 1.96, Xuanzhu Biopharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.96, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xuanzhu Biopharmaceutical Co's current PB Ratio of 4.41 is 125% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Xuanzhu Biopharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xuanzhu Biopharmaceutical Co's current PB Ratio is 4.41, which is 74% below median its own 10-year median of 17.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xuanzhu Biopharmaceutical Co stock overvalued right now?
Xuanzhu Biopharmaceutical Co (HKSE:02575) has a current PB Ratio of 4.41. The current PB Ratio is 4.41, which is 74% below median its 10-year median of 17.11 and 125% above the Drug Manufacturers industry median of 1.96. Xuanzhu Biopharmaceutical Co's overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Xuanzhu Biopharmaceutical Co (HKSE:02575), the current PB Ratio is 4.41 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Xuanzhu Biopharmaceutical Co Ltd is an innovation-driven biopharmaceutical company in China, leveraging its understanding of China's pharmaceutical industry and insights of its clinical needs to improve patient health and life. It has over ten drug assets under active development covering digestive diseases, oncology, and NASH. Its track record also includes the successful development of four drug candidates that were subsequently transferred and/or out-licensed to pharmaceutical companies. Its pipeline is staggered and complementary in structure, covering both validated targets with druggability as well as new mechanisms of action and drug modalities, established therapeutic areas such as oncology, and high-growth potential therapeutic areas such as NASH.
11GF Score
Get the complete analysis for HKSE:02575
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02575 has been successfully added to your 
